- US FDA approves Gilead cancer gene therapy; price set at $373000Reuters
- These 5 Top Stocks Are Moving Late On News: S&P 500 FuturesInvestor’s Business Daily
- Move over, Novartis: Kite and Gilead break into CAR-T market with early axi-cel nodFiercePharma
- UPDATED: FDA follows through with a groundbreaking OK for Yescarta, Gilead’s new CAR-T breakthroughEndpoints News
- FDA Approves Second Gene-Altering Treatment for CancerNew York Times